A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594
(Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.